Expression of ERCC1 and class III β-tubulin is associated with the survival of resected stage III non-small cell lung cancer patients treated with induction chemoradiotherapy using carboplatin-taxane

  • Authors:
    • Cheng-Long Huang
    • Kyuichi Kadota
    • Dage Liu
    • Masaki Ueno
    • Nariyasu Nakasima
    • Shinya Ishikawa
    • Masashi Gotoh
    • Noriyuki Misaki
    • Sung-Soo Chang
    • Hiroyasu Yokomise
  • View Affiliations

  • Published online on: May 1, 2010     https://doi.org/10.3892/etm_00000069
  • Pages: 445-451
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Several molecules have been proven to be associated with responsiveness to chemotherapy. A clinical study on the expression of excision repair cross-complementing (ERCC)-1 and class III β-tubulin was conducted in advanced stage non-small cell lung cancer (NSCLC) patients. We investigated 34 resected stage III NSCLC patients treated with induction chemoradiotherapy using carboplatin-taxane. Immunohistochemistry was performed to evaluate the intra-tumoral expression of ERCC1 and class III β-tubulin. Nineteen tumors (55.9%) were ERCC1-high and 11 (32.4%) were class III β-tubulin-high. There was no correlation between ERCC1 and class III β-tubulin expression (r=0.208). Regarding the pathological effect of induction therapy, the percentage of ERCC1-positive tumor cells was lower in tumors with a major response than in tumors with a minor response (P=0.0851). The percentage of class III β-tubulin-positive tumor cells was significantly lower in tumors with a major response than in tumors with a minor response (P=0.0105). Regarding patient survival, the overall survival was significantly higher in patients with ERCC1-low tumors than in those with ERCC1-high tumors (P=0.0034). The overall survival was also significantly higher in patients with class III β-tubulin-low tumors than in those with class III β-tubulin-high tumors (P=0.0185). Cox regression analysis also demonstrated that ERCC1 (P=0.0467) and class III β-tubulin statuses (P=0.0237) were significant prognostic factors. Co-evaluations of the intratumoral expression of ERCC1 and class III β-tubulin are clinically useful for identifying patient populations responsive to chemotherapy using carboplatin-taxane.
View Figures
View References

Related Articles

Journal Cover

May-June 2010
Volume 1 Issue 3

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Huang C, Kadota K, Liu D, Ueno M, Nakasima N, Ishikawa S, Gotoh M, Misaki N, Chang S, Yokomise H, Yokomise H, et al: Expression of ERCC1 and class III β-tubulin is associated with the survival of resected stage III non-small cell lung cancer patients treated with induction chemoradiotherapy using carboplatin-taxane . Exp Ther Med 1: 445-451, 2010.
APA
Huang, C., Kadota, K., Liu, D., Ueno, M., Nakasima, N., Ishikawa, S. ... Yokomise, H. (2010). Expression of ERCC1 and class III β-tubulin is associated with the survival of resected stage III non-small cell lung cancer patients treated with induction chemoradiotherapy using carboplatin-taxane . Experimental and Therapeutic Medicine, 1, 445-451. https://doi.org/10.3892/etm_00000069
MLA
Huang, C., Kadota, K., Liu, D., Ueno, M., Nakasima, N., Ishikawa, S., Gotoh, M., Misaki, N., Chang, S., Yokomise, H."Expression of ERCC1 and class III β-tubulin is associated with the survival of resected stage III non-small cell lung cancer patients treated with induction chemoradiotherapy using carboplatin-taxane ". Experimental and Therapeutic Medicine 1.3 (2010): 445-451.
Chicago
Huang, C., Kadota, K., Liu, D., Ueno, M., Nakasima, N., Ishikawa, S., Gotoh, M., Misaki, N., Chang, S., Yokomise, H."Expression of ERCC1 and class III β-tubulin is associated with the survival of resected stage III non-small cell lung cancer patients treated with induction chemoradiotherapy using carboplatin-taxane ". Experimental and Therapeutic Medicine 1, no. 3 (2010): 445-451. https://doi.org/10.3892/etm_00000069